Introduction {#s2}
============

Diabetes is an established risk factor for coronary heart disease (CHD). There is considerable interest in whether circulating markers of glucose metabolism are associated with risk of CHD in people without diabetes. Various measures of dysglycaemia have been assessed in long-term studies of CHD, notably: fasting glucose concentration (an indicator of steady-state glucose metabolism at the time of measurement); post-load glucose concentration (an indicator of immediate response to glycaemic stress); and glycated haemoglobin (HbA~1c~, an indicator of average blood glucose concentration over the previous 1--3 mo) [@pmed.1000278-Goldstein1],[@pmed.1000278-Beckman1]. It has been proposed that markers of dysglycaemia may be log-linearly and importantly associated with risk of subsequent vascular disease at all levels (including below the thresholds defining diabetes) [@pmed.1000278-Coutinho1]--[@pmed.1000278-DECODE1], but available data are not conclusive. For example, the US Preventive Services Task Force recently stated that published prospective data on fasting glucose and CHD were "inconsistent" and had "serious limitations" [@pmed.1000278-Helfand1].

We report new data from the population-based Reykjavik prospective study on associations of fasting and post-load glucose levels with CHD incidence across the range of glucose values. We also did a systematic review and meta-analysis of tabular data from 26 additional relevant Western cohorts [@pmed.1000278-Ulmer1]--[@pmed.1000278-Khaw1]. In total, the current report considers data on 303,961 participants, including 16,982 incident CHD cases.

Methods {#s3}
=======

Participants in the Reykjavik Study {#s2a}
-----------------------------------

The Reykjavik study has been described in detail previously [@pmed.1000278-Jonsdottir1]. Men born during 1907--1934 and women born during 1908--1935 who were resident in Reykjavik, Iceland and its adjacent communities on 1 December 1966 were identified in the national population register and invited to participate during five stages of recruitment between 1967 and 1991. A total of 8,888 male and 9,681 female participants without a history of myocardial infarction agreed to take part (72% response rate). Nurses administered questionnaires, made physical measurements, recorded an electrocardiogram, and collected fasting blood samples (taken after ≥8 h of fasting) at baseline. All participants have been monitored subsequently by central registries for occurrence of major cardiovascular morbidity (based on WHO MONICA \[Multinational Monitoring of Trends and Determinants in Cardiovascular Disease\] or similar criteria) or cause-specific mortality (based on a death certificate with International Classification of Diseases \[ICD\] 9 codes 410--414), with a loss to follow-up of only about 0.6% to date. During mean follow-up of 23.5 y, nonfatal MI or fatal CHD was recorded in a total of 4,664 participants, of whom 4,490 (including 3,088 men and 1,402 women) had no history of diabetes at baseline. Data were not available on incidence of stroke, diabetes, or microvascular disease. The National Bioethics Committee and the Data Protection Authority of Iceland approved the study protocol, and participants gave informed consent.

Laboratory Methods {#s2b}
------------------

Fasting glucose measurement was carried out in fresh capillary whole blood within hours of blood sampling at the initial examination by a micro method on a Technicon Autoanalyzer using a modification of the W. S. Hoffman method (coefficient of variation 4%) and standardised to the Hyland Normal Clinical Chemistry Control Serum (Nygaard A/S, Oslo) [@pmed.1000278-Hoffman1]. Post-load glucose levels were measured 60 and 90 min after ingestion of a 50 g glucose load. Lipid and other measurements involved standard assays, as previously described [@pmed.1000278-Jonsdottir1]. HbA~1c~ measurements were not done.

Statistical Methods {#s2c}
-------------------

The shapes of associations with CHD risk in the Reykjavik study were characterized by calculation of hazard ratios (HRs) across tenths of glucose values, including the full range of glucose values observed. Cox proportional hazards regression models were adjusted for age, sex, smoking status, systolic blood pressure, total cholesterol, and body mass index (BMI). Ninety-five percent confidence intervals (95% CIs) were estimated from the variances that reflect the amount of information underlying each group (including the reference group) [@pmed.1000278-Easton1]. Subsidiary analyses corrected for regression dilution using serial glucose measurements made in 370 of the participants (mean interval: 12 y) [@pmed.1000278-Clarke1]. In 18,333 participants without evidence of diabetes at baseline (i.e., no self-reported history and fasting blood glucose \<7 mmol/l), HRs for CHD were calculated per 1 mmol/l higher glucose concentration. Impaired fasting glucose was defined using published guidelines [@pmed.1000278-Expert1]. Effect-modification was investigated by formal tests of interaction.

Systematic Review {#s2d}
-----------------

Three of the current investigators (NS, RG, and SRKS) sought prospective studies published between January 1970 and September 2009 that had reported on associations of fasting blood glucose, post-load glucose, and/or HbA~1c~ with incident CHD. Details of the search strategies and a flow diagram are provided in [Text S1](#pmed.1000278.s008){ref-type="supplementary-material"}. Published studies were identified through electronic searches not limited to the English language (using MEDLINE, EMBASE, BIOSIS, and the Science Citation Index), by scanning reference lists of articles identified for all relevant studies (including review articles), and by hand searching of selected general medical journals (i.e., *BMJ, JAMA, Lancet, NEJM, PLoS Medicine, Annals of Internal Medicine, Archives of Internal Medicine*), cardiovascular/diabetes journals (i.e., *Circulation, Diabetes, Diabetes Care, European Heart Journal, Journal of the American College of Cardiology*), and epidemiological journals (i.e., *American Journal of Epidemiology, International Journal of Epidemiology*). Studies were eligible for inclusion if they: (1) did not select participants on the basis of having pre-existing vascular disease; (2) were located in Western Europe, North America, or Australasia (a restriction to reduce potential heterogeneity due to factors related to geographical location, e.g., ethnicity; see [Discussion](#s5){ref-type="sec"}); (3) had more than 1 y of follow-up; and (4) reported on nonfatal MI (as defined by WHO MONICA or equivalent criteria, i.e., involving diagnosis based on clinical symptoms, electrocardiographic abnormalities, and/or cardiac biomarkers) and/or fatal CHD (defined by ICD criteria). Eligibility for inclusion of identified studies was considered by two investigators (RG and SRKS). Any disagreement was resolved by discussion and, if necessary, by the deciding vote of a third reviewer (NS).

A request for tabular data was sent to investigators of every eligible study identified. The following information was sought (excluding participants with a self-reported history of diabetes and/or fasting blood glucose ≥7 mmol/l at baseline), according to a uniform protocol: number of incident CHD outcomes recorded; relative risk (RR with 95% CI for CHD per unit higher dysglycaemia marker, initially after adjustment for age and sex only and then after additional adjustment for smoking status, systolic blood pressure, lipid concentrations, and BMI); the content of the glucose load and interval before post-load venipuncture; number of participants with resurvey measurements; interval between such measurements; and degree of long-term within-person variability of dysglycaemia markers ([Table S1](#pmed.1000278.s004){ref-type="supplementary-material"}). Accuracy of the information supplied was cross-checked against published data. In the few instances of apparent discrepancy, resolution was achieved through consultation with study investigators.

Meta-analysis {#s2e}
-------------

Summary RRs for CHD per unit higher dysglycaemia marker were calculated by pooling study-specific estimates using a random effects model. Analyses involved only within-study comparisons. As regards units of analysis used, 1 mmol/l higher fasting glucose corresponds approximately to 1-standard deviation (SD) higher levels; 1 mmol/l higher post-load glucose corresponds approximately to 2-SD higher levels; and 1% higher HbA~1c~ corresponds approximately to 1-SD higher levels. Consistency of findings was assessed by standard χ^2^ tests and the *I* ^2^ statistic [@pmed.1000278-Higgins1]. Diversity at the study level was investigated by grouping studies by recorded characteristics and by meta-regression (including study size and duration of follow-up as continuous variables). Small-study effects were investigated [@pmed.1000278-Egger1].

Results {#s4}
=======

Reykjavik Study {#s3a}
---------------

Baseline conventional risk factors were significantly higher in those who subsequently recorded incident CHD than in non-cases, as were fasting and 1-h post-load glucose levels ([Table S2](#pmed.1000278.s005){ref-type="supplementary-material"}). Fasting and 1-h post-load glucose levels were each significantly correlated with several conventional risk factors and with each other ([Table S3](#pmed.1000278.s006){ref-type="supplementary-material"}). In people without diabetes at baseline, serial measurements yielded intra-class correlation coefficients of 0.61 (95% CI 0.54--0.67) for fasting blood glucose, 0.50 (0.42--0.57) for 1-h post-load glucose, 0.59 (0.51--0.67) for total cholesterol, and 0.65 (0.54--0.77) for systolic blood pressure. In people who had no history of diabetes at baseline, HR for CHD---adjusted for age, sex, recruitment period, smoking status, systolic blood pressure, total cholesterol, and BMI (henceforth, "adjusted HR")---was 2.37 (1.79--3.14) in those with fasting glucose ≥7.0 mmol/l compared with those \<7.0 mmol/l. (HR was 1.67 \[1.36--2.02\] with fasting glucose ≥6.1 mmol/l compared with those \<6.1 mmol/l, a definition of diabetes proposed for studies involving capillary whole blood samples [@pmed.1000278-1].) In analyses across tenths of fasting glucose values, adjusted HRs for CHD were generally weak and nonsignificant at levels below 7 mmol/l ([Figure 1](#pmed-1000278-g001){ref-type="fig"}). Findings were broadly similar for 1-h post-load glucose levels ([Figure 2](#pmed-1000278-g002){ref-type="fig"}) and in analyses that: adjusted for age and sex only ([Figure S1](#pmed.1000278.s001){ref-type="supplementary-material"}); corrected for regression dilution ([Figure S2](#pmed.1000278.s002){ref-type="supplementary-material"}); assessed 90-min post-load glucose (available upon request from NS).

![Risk of CHD across tenths of baseline fasting glucose levels in the Reykjavik Study.\
All hazard ratios are adjusted for age, sex, recruitment period, smoking status, systolic blood pressure, total cholesterol, and BMI, and all are compared to individuals in the middle tenth of the distribution. The grey area denotes the 95% CI of the reference group. Analyses involved the full range of glucose values (i.e., including individuals with glucose levels in the diabetic range). To limit any bias related to having a diagnosis of diabetes (e.g., medication use, lifestyle changes), however, individuals with a known history of diabetes at the baseline survey were excluded.](pmed.1000278.g001){#pmed-1000278-g001}

![Risk of CHD across tenths of baseline 1 h post-load glucose levels in the Reykjavik Study.\
All hazard ratios are adjusted for age, sex, recruitment period, smoking status, systolic blood pressure, total cholesterol, and BMI, and all are compared to individuals in the middle tenth of the distribution. The grey area denotes the 95% CI of the reference group. Analyses involved the full range of glucose values (i.e., including individuals with glucose levels in the diabetic range). To limit any bias related to having a diagnosis of diabetes (e.g., medication use, lifestyle changes), however, individuals with a known history of diabetes at the baseline survey were excluded.](pmed.1000278.g002){#pmed-1000278-g002}

In people who had no history of diabetes and fasting glucose \<7.0 mmol/l at baseline, adjusted HR for CHD was 0.95 (0.89--1.01) per 1 mmol/l higher fasting glucose and 1.03 (1.01--1.05) per 1 mmol/l higher 1-h post-load glucose. Similar findings were observed in analyses that: explored HRs in a range of clinically relevant subgroups ([Figure S3](#pmed.1000278.s003){ref-type="supplementary-material"}); assessed HRs in 5-y intervals of follow-up (available upon request); or excluded people with post-load glucose levels ≥11.1 mmol/l (available upon request). Compared with individuals with fasting glucose \<5.6 mmol/l, adjusted HRs for CHD were: 1.27 (0.96--1.68) with fasting glucose levels 6.1--7.0 mmol/l and 1.08 (0.87--1.33) with fasting glucose levels 5.6--6.1 mmol/l (i.e., corresponding to categories of fasting glucose concentration used to define impaired fasting glucose).

Meta-analysis {#s3b}
-------------

Thirty-five potentially eligible prospective studies were identified, including the present Reykjavik study. Of these studies, 27 contributed data to the current analysis, yielding 303,961 participants, including 16,982 incident CHD cases ([Table S4](#pmed.1000278.s007){ref-type="supplementary-material"}). This information constitutes \>85% of the relevant incident CHD cases identified ([Text S1](#pmed.1000278.s008){ref-type="supplementary-material"} lists the noncontributing studies). Fourteen of the contributing studies were based in Western Europe, ten in North America, and three in Australia. All recruited participants from population registers or occupational settings. Fifty-six percent of the participants were male, and most were middle-aged and of European descent. For fasting glucose, there were 23 contributing studies, yielding 255,171 participants and 10,808 incident CHD cases. All studies used standard glucose assay methods and reported generally similar mean glucose values ([Table S4](#pmed.1000278.s007){ref-type="supplementary-material"}), with four studies involving whole blood samples and 19 plasma or serum. For post-load glucose, there were 15 contributing studies, yielding 102,382 participants and 12,652 cases. Ten of these studies measured glucose 2 h after a 75 g load and five studies used other methods. For HbA~1c~, there were nine contributing studies, yielding 49,099 participants and 1,639 cases.

Seven studies [@pmed.1000278-Eberly1],[@pmed.1000278-CruzVidal1],[@pmed.1000278-Welborn1],[@pmed.1000278-Yarnell1],[@pmed.1000278-Pyrl1],[@pmed.1000278-Orencia1] provided information on long-term serial measurements, yielding weighted intra-class correlation coefficients of 0.67 (0.66--0.69) for fasting glucose (7,834 participants, mean interval 3.5 y), 0.48 (0.46--0.50) for post-load glucose (5,617 participants, 3.5 y), and 0.69 (0.68--0.70) for HbA~1c~ (6,370 participants, 4 y). Combined RRs, adjusted for age and sex only, were: 1.12 (1.06--1.18) per 1 mmol/l higher fasting glucose; 1.08 (1.04--1.11) per 1 mmol/l higher post-load glucose; and 1.34 (1.24--1.44) per 1% higher HbA~1c~. Corresponding RRs adjusted for several conventional risk factors were: 1.06 (1.00--1.12) with fasting glucose; 1.05 (1.03--1.07) with post-load glucose; and 1.20 (1.10--1.31) with HbA~1c~ ([Figure 3](#pmed-1000278-g003){ref-type="fig"}). There was heterogeneity in each RR (*I* ^2^ of 82% \[74--88\], 88% \[83--93\], and 42% \[0--69\], respectively), but little of it was explained by characteristics recorded ([Figure 4](#pmed-1000278-g004){ref-type="fig"}). For fasting glucose, RRs were very similar in studies involving whole blood samples and in those with plasma or serum (1.05 versus 1.06). For post-load glucose, RRs were very similar in studies measuring glucose 2 h after a 75 g glucose load and in those in studies using other methods (1.05 versus 1.05). Subsidiary analyses that omitted any particular study did not materially alter the findings (e.g., omission of the Reykjavik study yielded adjusted RRs of 1.06 \[1.00--1.12\] with fasting glucose and 1.05 \[1.03--1.08\] with post-load glucose; and omission of the San Antonio Heart Study, which had unusually narrow CIs given its size, yielded adjusted RRs of 1.02 \[0.99--1.06\] with fasting glucose and 1.04 \[1.02--1.07\] with post-load glucose). There was no good evidence of small study effects (e.g., Egger test *p*\>0.1 for each marker assessed). Literature-based analyses yielded broadly similar RRs with fasting glucose in the non-contributing studies to those reported here ([Text S1](#pmed.1000278.s008){ref-type="supplementary-material"}).

![Prospective studies of markers of dysglycaemia and CHD risk in individuals without diabetes in Western populations.\
Analyses were restricted to individuals who did not have a self-reported history of type 2 diabetes or had a fasting blood glucose \<7.0 mmol/l at baseline. Risk estimates are presented per 1 mmol/l higher fasting and post-load glucose, and per 1% higher HbA~1c~. Abbreviations as listed in [Table S2](#pmed.1000278.s005){ref-type="supplementary-material"}.](pmed.1000278.g003){#pmed-1000278-g003}

![Prospective studies of fasting and post-load glucose and CHD risk in individuals without diabetes in Western population, grouped by study characteristics.\
Meta-regression analyses separately considered each characteristic presented. \*Assessed as continuous factors.](pmed.1000278.g004){#pmed-1000278-g004}

Discussion {#s5}
==========

The current data indicate that fasting and post-load glucose and HbA~1c~ each have reasonably high degrees of long-term within-person reproducibility (i.e., broadly comparable to such reproducibility values for total cholesterol and systolic blood pressure). The current meta-analysis of data from population-based Western prospective studies involving a total of \>300,000 people (≈17,000 incident CHD cases) indicate that fasting glucose concentration is modestly associated with CHD risk in people without diabetes, i.e., RR for CHD was about 1.06 per 1 mmol/l higher fasting glucose. Furthermore, in the Reykjavik prospective study, RRs were generally modest and nonsignificant across glucose values below the diabetes definition (i.e., fasting glucose \<7 mmol/l). We observed similar results in relation to post-load glucose. The current findings contrast with those from some smaller previous studies, which have suggested that glucose values are log-linearly and more strongly associated with CHD risk (including at glucose values lower than those defining diabetes). Because previous epidemiological estimates have influenced scientific guideline statements [@pmed.1000278-Task1], clinical risk assessment strategies [@pmed.1000278-Kahn1], burden of disease estimates [@pmed.1000278-Danaei1], and public health policy recommendations [@pmed.1000278-Avendano1], it may be helpful to review such efforts in the light of the current updated epidemiological evidence. Careful consideration may also need to be given to the design and interpretation of trials of CHD prevention using glucose-lowering agents in people without diabetes, as the current findings suggest that trial sample sizes required may be larger than previously anticipated [@pmed.1000278-Origin1]--[@pmed.1000278-The1].

In contrast with findings for glucose concentration, the current meta-analysis has indicated a RR for CHD of 1.20 per 1% higher HbA~1c~ in people without diabetes. Although RRs for CHD appear stronger with HbA~1c~ than those with glucose concentration, this possibility requires careful interpretation because: (1) the comparison is an indirect one (i.e., fasting glucose and HbA~1c~ measurements were typically not made in the same participants) and (2) fewer than one-fifth as many incident CHD cases have been reported with HbA~1c~ as with glucose concentration (so associations with HbA~1c~ cannot be quantified as reliably as those with glucose levels). Nevertheless, because the current data suggest that fasting glucose and HbA~1c~ have similar levels of within-person variability over several years, such variability seems unlikely to account for differences seen in RRs with different measures of dysglycaemia. It remains uncertain whether HbA~1c~ is a more informative measure of dysglycaemia than are fasting or post-load glucose levels, more accurately reflects processes relevant to vascular damage in response to glycation, or some combination of these possibilities [@pmed.1000278-Beckman1],[@pmed.1000278-Khaw2].

The strengths and potential limitations of this study merit consideration. For fasting glucose, the Reykjavik study involves more incident CHD cases than in any previous prospective study. It identified participants in population registers, achieved high response and follow-up rates, and entailed robust ascertainment of incident MI and fatal CHD. We have demonstrated the validity of the glucose measurements in capillary whole blood samples by showing: the expected strong associations of fasting glucose levels with CHD in people with values ≥7.0 mmol/l; long-term within-person consistency of glucose concentration comparable to that for systolic blood pressure and total cholesterol concentration; and similar findings as in previous studies that used plasma or serum. For post-load glucose, RRs in the Reykjavik study (involving assessment 1 h after ingestion of a 50 g glucose load) were very similar to RRs in studies involving assessment 2 h after ingestion of a 75 g glucose load.

As findings in the Reykjavik study were reinforced by a meta-analysis of tabular data from 26 other long-term prospective studies located in ten Western countries, it increases the likelihood that these results can be extrapolated, at least to other Western populations. Although our review focused only on Western cohorts to reduce heterogeneity, it may be relevant to note that the largest available prospective study in East Asia (≈3,100 incident MI outcomes) has reported similar findings to those described here, concluding that fasting glucose concentration has no clear association with MI risk below the diabetes definition [@pmed.1000278-Sung1]. Our meta-analysis included \>85% of the relevant data identified by the systematic review (and a literature-based sensitivity analyses of noncontributing studies yielded broadly similar findings). Although we noted heterogeneity, it was not explained by the characteristics recorded here. Because some previous reviews did not consistently exclude people with diabetes at baseline [@pmed.1000278-Coutinho1],[@pmed.1000278-Levitan1] or involved only fatal CHD [@pmed.1000278-DECODE1], it is difficult to compare their RRs directly with the RRs observed here. A more detailed consideration of available prospective studies, perhaps on the basis of combination of individual participant data, will enable more reliable analyses under a broader range of circumstances and a more detailed investigation of potential sources of diversity.

Conclusions {#s4a}
-----------

In people without diabetes, fasting and post-load glucose levels were modestly associated with CHD risk. Associations of HbA~1c~ with CHD risk in such people appeared somewhat stronger. Scientific guidelines, policies, and trial designs premised on the existence of strong, log-linear associations of fasting and post-load glucose concentration with CHD risk may benefit from review in light of these epidemiological findings.
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Note Added in Proof {#s7}
===================

Investigators of an additional study of fasting glucose concentration and CHD [@pmed.1000278-Preiss1], involving a further 6,447 participants and 862 incident CHD cases, provided tabular data while this article was in proof. After addition of these data to the meta-analysis, the combined adjusted relative risk for CHD was 1.05 (1.00--1.10) per 1 mmol/l higher fasting glucose concentration (24 cohorts, 11,670 cases, 261,618 participants).
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